drugset / Trial / NCT01403311

A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

NCT01403311

NaSingle-groupOpen-labelTreatment

Summary

This study aims to determine the safety and utility of using 5-Aminolevulinic Acid (ALA) in removing malignant brain tumors during surgery.

Timeline

Start
2010-10
Primary completion
2011-12
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent 30 mg/kg Oral

Indications